24/7 Wall Street
03 Aug 2026, 15:44 UTC · 6w ago
Verdict
Headline leans bullish. We score ABT +0.40 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.40moderately bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish
Abbott Laboratories raised its full-year adjusted EPS guidance to a range of $5.45 to $5.60.
More positive than 91% of claims this week
Abbott's CEO expects accelerating sales and earnings growth in the second half of 2026.
So whatForward-looking positive guidance from leadership typically boosts investor sentiment and risk appetite for the stock.
Continue reading
5 related stories
More positive than 64% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 77% of claims this week
Abbott achieved its fifth consecutive adjusted EPS beat with a Q2 result of $1.31 versus $1.28 consensus.
More positive than 65% of claims this week
Abbott's GAAP earnings were severely impacted by the $21 billion Exact Sciences acquisition, resulting in a 47.5% reported quarterly earnings decline.
More negative than 66% of claims this week
Abbott experienced segment weakness in Nutrition (-3.1%), U.S. Structural Heart (-9.8%), and rapid/molecular diagnostics (-7.3%).
More negative than 66% of claims this week
Which stocks this story touches
More positive than 64% of ticker scores this week
Despite GAAP losses from an acquisition, the company raised guidance and had its fifth straight adjusted EPS beat.
More negative than 74% of ticker scores this week
Shares collapsed over 50% year-to-date following two consecutive guidance cuts.
More negative than 68% of ticker scores this week
Shares are down over 14% year-to-date.
More negative than 68% of ticker scores this week
Stock is down nearly 10% year-to-date with split analyst coverage.
More positive than 45% of ticker scores this week
Mentioned as a successful historical stock pick by an analyst.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as a competitor to Abbott's CGM business.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market Watch
33m ago
More positive than 77% of relationship scores this week
[mutual] Abbott competes against Dexcom in the continuous glucose monitor (CGM) market.
More positive than 36% of relationship scores this week
[mutual] The article identifies Boston Scientific as part of a stable peer set for Abbott.
More positive than 36% of relationship scores this week
[mutual] The article identifies Danaher as part of a stable peer set for Abbott.
More positive than 36% of relationship scores this week
[mutual] The article identifies Medtronic as part of a stable peer set for Abbott.
−2.9%
Price is moving against the score
$102.60 vs $105.70 close before publication (Jul 31) · not market-adjusted
ABT chart →
